<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-857
Date of Submission: 2024-08-13

This report was submitted by a Pharmacist from Quinn-Blankenship Medical Center concerning patient ANON-PX-2680. The subject is a 87-year-old other with a significant medical history including chronic kidney disease, migraines, type 2 diabetes, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Oral route at a dosage of 58mg, initiated on 2024-06-28 for Pain and inflammation with the course ongoing.

On approximately 2024-08-02, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Maculopapular Rash, Pruritus. The Dizziness was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Maculopapular Rash was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed suddenly and advised lay. The current patient status regarding this symptom is 'Fatal'. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2024-857
report_date: '2024-08-13'
patient_details:
  patient_id: ANON-PX-2680
  gender: Other
  relevant_history:
  - chronic kidney disease
  - migraines
  - type 2 diabetes
  - seasonal allergies
  age_at_reaction: 87
suspected_drugs:
- drug_name: Ibuprofen
  dosage: 58mg
  route_of_administration: Oral
  start_date: '2024-06-28'
  indication_for_use: Pain and inflammation
  drug_class: NSAID
adverse_reactions:
- symptom_name: Dizziness
  onset_date: '2024-08-02'
  severity: Life-threatening
  outcome: Recovering
  intervention_required: false
- symptom_name: Maculopapular Rash
  onset_date: '2024-08-02'
  severity: Severe
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed suddenly and advised lay.
- symptom_name: Pruritus
  onset_date: '2024-08-02'
  severity: Moderate
  outcome: Unknown
  intervention_required: false
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Positive rechallenge
  naranjo_score: 4
reporting_facility: Quinn-Blankenship Medical Center
reporter_type: Pharmacist
